Number of Antibody-Drug Conjugates in Active Clinical Development Doubled during 2013-2016, Says La Merie Publishing in Study Available at MarketPubli
11 Jan 2017 • by Natalie Aster
LONDON – The number of antibody-drug conjugates(ADCs) in active clinical development doubled (from 33 to 65) during April 2016 – late 2016. Eight among them are currently in late stage of development or are passing regulatory review. Over twenty ADCs are at present in the IND stage or are undergoing IND-enabling studies. Meantime, the number of ADCs discontinued from clinical development increased as well.
Along with the escalating number of ADCs in development as well as rising number of companies with in-house ADC technology development, novel payloads are currently being evaluated in early clinical studies.
The competitive intelligence report by La Merie Publishing, “Antibody-Drug Conjugate Pipeline Review by target, drug, phase and company”, presents a comprehensive evaluation of the competitive landscape in the antibody-drug conjugates (ADCs) and uncovers reliable info on the products in the pipeline. The publication offers data on 58 preclinical stage ADC projects and also highlights 22 ADC discovery programs. Moreover, the study lists the existing ADCs by drug payload, target and company; and also comprises a compilation of currently active and discontinued ADC research and development initiatives. Additionally, the report touches upon company-specific R&D pipelines of ADCs.
For other research reports prepared by La Merie Publishing, follow to this Market Publishers’ catalogue.